Effective Ki-۶۷ Reduction by Short-Term Administration of Letrozole Before Surgery in (Hormone-Positive) Breast Cancer

Background & Objective: Antigen Ki-۶۷ (histone-based nuclear protein) is a static marker of tumor cell proliferation and growth and is commonly measured to indicate the effect of treatment in breast cancer patients. This single-arm trial study aimed to evaluate the effect of short-term endocrine therapy (letrozole) on Ki-۶۷ levels in menopausal women with early hormone-positive breast cancer who were referred to two university hospitals.Methods: Patients with a pre-treatment Ki۶۷ of ۵% or less were excluded from the study. Participants (n=۲۵) received oral letrozole (۲.۵ mg daily) seven days before surgery. Ki-۶۷% on both the biopsy and the surgical specimens were measured and compared.Results and Conclusion: The mean age of patients was ۶۲±۹.۴ (۴۸-۸۳ years). Our result indicated that consumption of letrozole before surgery for hormone-positive breast cancer can significantly decrease the level of Ki-۶۷ (۲۳.۲۴±۹.۷۴ vs. ۱۶.۹۲±۹.۵۵, P=۰.۰۰۱ by paired t-test), with no drug-related adverse events.

کلیدواژه ها:

Breast cancer ، Ki-۶۷ Antigen ، Letrozole ، Postmenopause